Evolution of the Average Target: Dermapharm Holding SE

Evolution of the Average Target - Dermapharm Holding SE

Evolution of the Target Price: Dermapharm Holding SE

Evolution of the Target Price - Dermapharm Holding SE

Changes in Analyst Recommendations: Dermapharm Holding SE

bf30a5b18d7f408bac6e4eda0142.-9yUfGCHbBGRwsgOFzm31fwFZboluetLH4ozZWrglI4.lOXnME33WFXirKRZIAzfo709V_5g4NwtKcNjVFOQ4OKMha0UMvYjXqCxqw~a464fa61057e1f0274a1fa8609d1f55b
05:09am Dermapharm Holding SE : Jefferies is Neutral ZD
09-03 Dermapharm Holding SE : Jefferies remains Neutral ZD
08-27 Dermapharm Holding SE : Receives a Buy rating from Berenberg ZD
08-25 Dermapharm Holding SE : Jefferies gives a Neutral rating ZD
08-25 Jefferies keeps Dermapharm at 'Hold', target €44 DP
08-11 Dermapharm Holding SE : Jefferies remains Neutral ZD
07-17 Dermapharm shares slide, BaFin probes annual financial statements DP
05-27 DERMAPHARM : Jefferies remains Neutral ZD
05-27 Jefferies raises Dermapharm target to 44 euros - 'Hold' DP
05-14 Dermapharm hits highest level since August 2022 DP
05-14 DERMAPHARM : Berenberg reaffirms its Buy rating ZD
05-13 Dermapharm Confirms Its Guidance After a Strong First Quarter Zonebourse
03-31 Alstom gains momentum, Inventiva underperforms Zonebourse
03-31 DERMAPHARM : Jefferies reiterates its Neutral rating ZD
03-10 DERMAPHARM : Jefferies gives a Neutral rating ZD
03-10 Dermapharm in the green as full-year EBITDA improves Zonebourse
03-10 DERMAPHARM : Jefferies gives a Neutral rating ZD
03-09 Jefferies Maintains 'Hold' Rating on Dermapharm - Target 34 Euros DP
11-27 DERMAPHARM : Jefferies reiterates its Neutral rating ZD
11-13 DERMAPHARM : Jefferies reiterates its Neutral rating ZD
25-09-08 DERMAPHARM : Gets a Neutral rating from Jefferies ZD
25-08-28 Jefferies downgrades affect Cancom, Vorwerk, and Dermapharm DP
25-08-28 Jefferies Downgrades Dermapharm to 'Hold', Slashes Price Target to 34 Euros DP
25-08-28 DERMAPHARM : Jefferies lowers his opinion and switches to Neutral ZD
25-08-26 DERMAPHARM : Warburg Research reiterates its Neutral rating ZD

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+32.12%
+1.12%
-0.36%
+5.31%
-1.37%
+9.75%
-3.31%
+16.26%
-7.76%
+2.97%
Average +5.47%
Weighted average by Cap. +2.19%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
38.60EUR
Average target price
51.00EUR
Spread / Average Target
+32.12%
High Price Target
60.00EUR
Spread / Highest target
+55.44%
Low Price Target
44.00EUR
Spread / Lowest Target
+13.99%

Analyst Consensus Detail

Analyst consensus - Dermapharm Holding SE

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Dermapharm Holding SE
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Dermapharm Holding SE
  1. Stock Market
  2. Stocks
  3. DMP Stock
  4. Consensus Dermapharm Holding SE